111, Inc.

111, Inc.

NNASDAQ:YI
2.84
USD
0.00
(0.00%)
-1.12EPS
38.18MMarket Cap
Nov 26Next Earn
111, Inc.
NASDAQ:YI
(Nasdaq Stock Market)

Recent

price

2.84

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
108.24
118.84
359.17
482.92
995.61
1,498.3
1,622.32
1,773.11
1,676.17
1,443
1,194.9
Revenue per Share
-51.77
-30.79
-76.44
-61.05
-55.41
-80.76
-50.04
-46.58
-7.54
-7.63
-12.01
Basic EPS, GAAP
-49
-26.16
-1.1
-65.62
-17.3
-90.62
-6.58
-54.22
28.84
13.18
-4.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-83.3
-114.19
150.14
94.64
43.23
-20.86
-49.64
-68.22
-74.35
-79.93
-13.01
Book Value per Share
-83.94
-114.76
149.58
93.67
42.44
-21.45
-50.03
-68.49
-74.51
-80.03
-13.02
Tangible Book Value per Share
8
8
5
8
8
8
8
8
9
9
9
Basic Weighted Avg Shares
874
959
1,786
3,952
8,203
12,426
13,517
14,948
14,401
12,556
10,483
Sales/Revenue/Turnover
-41.69
-26.47
-22.42
-12.49
-5.77
-5.17
-2.74
-2.34
0.01
-0.02
-0.44
Operating Margin (%)
12
15
11
12
14
27
41
22
17
12
- -
Depreciation Expense
-363
-249
-380
-500
-457
-670
-417
-393
-65
-66
-105
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-41.5
-25.91
-21.28
-12.64
-5.57
-5.39
-3.08
-2.63
-0.45
-0.53
-1.01
Profit Margin (%)
729
529
1,193
708
1,243
672
511
188
307
171
17
Working Capital
- -
- -
- -
57
62
166
100
63
55
30
3
LT Debt
576
319
1,224
774
1,331
849
648
276
381
214
24
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-49.94
-80.51
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
207
37
38
LT Borrowings
- -
- -
- -
LT Finance Leases
30
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
157
396
259

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,125
270
254
Cash, Cash Equivalents & STI
561
53
52
Accounts Receivable, Net
260
27
27
Inventories
998
147
132
Total Current Liabilities
1,954
249
237
Payables & Accruals
1,557
212
198
ST Debt
207
37
38
Deferred Revenue
144
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-24.61%
-43.69%
Free Cash Flow
- -
171.99%
-53.72%
Net Income, GAAP
- -
-15.56%
2.55%
Sales/Revenue/Turnover
- -
10.88%
-12.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,528
3,424
3,601
3,848
14,401
2025
3,529
3,206
3,001
2,820
12,556
2026
2,362
2,300
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.61
-1.64
-1.99
-2.3
-7.54
2025
-2.04
-2.25
-1.49
-1.85
-7.63
2026
-4.21
-4.44
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
111, Inc. (NASDAQ: YI) operates a leading integrated online and offline healthcare platform in China, digitally connecting patients with pharmaceutical products and healthcare services through its B2C and B2B segments. The company offers online retail pharmacy services via 1 Drugstore, providing prescription drugs, over-the-counter medications, health and wellness products, and medical devices to individual consumers; internet hospital services through 1 Clinic, including online consultations, electronic prescriptions, and patient management; online wholesale pharmacy via 1 Drug Mall (also known as Yao Zhang Gui), serving pharmacies, clinics, and healthcare providers with pharmaceutical sourcing and supply chain solutions; cloud-based services for its extensive virtual pharmacy network; and omni-channel drug commercialization support for partners, encompassing digital marketing, patient education, data analytics, and pricing monitoring. Headquartered in Shanghai and founded in 2010 by Gang Yu and Junling Liu, 111, Inc. primarily serves the Chinese market with nationwide operations, employing around 1,238 people as of recent reports. Recent developments include sustained operational profitability for multiple consecutive quarters as of Q2 2025, with Q2 2024 marking income from operations of RMB3.3 million and positive cash flow; strategic partnerships such as a direct supply alliance with Beijing Scrianen Pharmaceutical in Q2 2024 to enhance drug distribution using big data and digital tools, an alliance named 1Pharmacy with ApicHope Pharmaceutical and others for innovative collaboration on exclusive products and traditional Chinese medicine, and agreements with Bayer Healthcare and Hainan Huluwa Pharmaceutical in 2024; acquisition of four new patents in 2024, increasing its total to 28 to bolster technological capabilities; and co-founders' strategic share purchases in September 2024 signaling confidence in growth amid ongoing digital transformation efforts.

Company News

  • Comparing 111 (NASDAQ:YI) & BrightSpring Health Services (NASDAQ:BTSG)

  • 111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

  • 111, Inc. Announces Establishment of the Special Committee

  • 111, Inc. Announces Establishment of the Special Committee

  • 111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company

  • 111, Inc. Announces Second Quarter 2026 Unaudited Financial Results

  • 111, Inc. Announces Second Quarter 2026 Unaudited Financial Results

  • Critical Review: 111 (NASDAQ:YI) and SBC Medical Group (NASDAQ:SBC)

  • 111, Inc. Announces First Quarter 2026 Unaudited Financial Results

  • 111, Inc. Announces First Quarter 2026 Unaudited Financial Results

  • 111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results

  • Reviewing 111 (NASDAQ:YI) & Hims & Hers Health (NYSE:HIMS)

  • Comparing Biotricity (OTCMKTS:BTCY) & 111 (NASDAQ:YI)

  • Head to Head Review: Veeva Systems (NYSE:VEEV) and 111 (NASDAQ:YI)

  • 111, Inc. Announces Third Quarter 2025 Unaudited Financial Results

  • Head to Head Contrast: Privia Health Group (NASDAQ:PRVA) & 111 (NASDAQ:YI)

  • 111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

  • 111, Inc. Announces First Quarter 2025 Unaudited Financial Results

  • 111, Inc. (YI) Q4 2024 Earnings Call Transcript

  • 111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results